132 related articles for article (PubMed ID: 8385564)
1. A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group.
Gesme DH; Jett JR; Schreffler DD; Su JQ; Mailliard JA; Foley JF; Krook JE; Maksymiuk AW; Hatfield AK; Ebbert LP
Cancer; 1993 May; 71(9):2723-6. PubMed ID: 8385564
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer.
Berger MZ; Kris MG; Gralla RJ; Marks LD; Potanovich LM; Dimaggio JJ; Heelan RT
Am J Clin Oncol; 1991 Apr; 14(2):124-6. PubMed ID: 1851387
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical investigation of amonafide.
Saez R; Craig JB; Kuhn JG; Weiss GR; Koeller J; Phillips J; Havlin K; Harman G; Hardy J; Melink TJ
J Clin Oncol; 1989 Sep; 7(9):1351-8. PubMed ID: 2549205
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588).
Chang AY; Tu ZN; Smith JL; Bonomi P; Smith TJ; Wiernik PH; Blum R
Invest New Drugs; 1995; 13(2):137-41. PubMed ID: 8617576
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH
Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma.
Fossella FV; Winn RJ; Holoye PY; Hallinan B; Raber MN; Hoelzer K; Young JA; Readling J; Bowers B; Hong WK
Invest New Drugs; 1992 Nov; 10(4):331-5. PubMed ID: 1336771
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of amonafide in advanced colorectal cancer: a SouthWest Oncology Group study.
Brown TD; Goodman PJ; Fleming T; Macdonald JS; Craig JB; Einstein AB
Anticancer Drugs; 1993 Feb; 4(1):49-50. PubMed ID: 8457714
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study.
Gallion HH; Liu PY; Alberts DE; O'Toole RV; O'Sullivan J; Mills G; Smith HO; Hynes HE
Gynecol Oncol; 1992 Aug; 46(2):230-2. PubMed ID: 1500027
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of amonafide in advanced sarcoma: a Southwest Oncology Group study.
Buys SS; Metch B; Balcerzak SP; Neefe JR; Stuckey WJ
Cancer Invest; 1994; 12(4):399-402. PubMed ID: 8032960
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results.
Chang AY; Kim K; Glick J; Anderson T; Karp D; Johnson D
J Natl Cancer Inst; 1993 Mar; 85(5):388-94. PubMed ID: 8094467
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of amonafide (nafidamide, NSC 308847) in advanced colorectal cancer.
O'Dwyer PJ; Paul AR; Hudes GR; Walczak J; Ozols RF; Comis RL
Invest New Drugs; 1991 Feb; 9(1):65-7. PubMed ID: 2026485
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of amonafide in advanced pancreatic adenocarcinoma.
Linke K; Pazdur R; Abbruzzese JL; Ajani JA; Winn R; Bradof JE; Daugherty K; Levin B
Invest New Drugs; 1991 Nov; 9(4):353-6. PubMed ID: 1804812
[TBL] [Abstract][Full Text] [Related]
13. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of amonafide in advanced and recurrent sarcoma patients.
Perez RP; Nash SL; Ozols RF; Comis RL; O'Dwyer PJ
Invest New Drugs; 1992 Jul; 10(2):99-101. PubMed ID: 1500272
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group study.
Marshall ME; Blumenstein B; Crawford ED; Thompson IM; Craig JB; Eisenberger M; Ahmann F
Am J Clin Oncol; 1994 Dec; 17(6):514-5. PubMed ID: 7977172
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer.
Kris MG; D'Acquisto RW; Gralla RJ; Burke MT; Marks LD; Fanucchi MP; Heelan RT
Am J Clin Oncol; 1989 Feb; 12(1):24-6. PubMed ID: 2536213
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of amonafide in patients with endometrial cancer: a Gynecologic Oncology Group Study.
Asbury R; Blessing JA; Reid GC; McGuire WP
Am J Clin Oncol; 1998 Aug; 21(4):406-7. PubMed ID: 9708643
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer.
Evans WK; Eisenhauer EA; Cormier Y; Ayoub J; Wierzbicki R; Laberge F; Shepherd FA
J Clin Oncol; 1990 Mar; 8(3):390-5. PubMed ID: 2155309
[TBL] [Abstract][Full Text] [Related]
19. Amonafide as first-line chemotherapy for metastatic breast cancer.
Kornek G; Raderer M; Depisch D; Haider K; Fazeny B; Dittrich C; Scheithauer W
Eur J Cancer; 1994; 30A(3):398-400. PubMed ID: 8204367
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of mitonafide in non-small cell lung cancer (NSCLC).
Casado A; Rosell R; García-Gómez R; Díaz-Rubio E; Pérez-Manga G; Font A; Benavides A; Martín M
Invest New Drugs; 1996; 14(4):415-7. PubMed ID: 9157079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
